Equillium (NYSE:EQ) Research Coverage Started at HC Wainwright

Investment analysts at HC Wainwright assumed coverage on shares of Equillium (NYSE:EQ) in a research note issued on Friday, AnalystRatings.com reports. The firm set a “buy” rating and a $14.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 154.55% from the stock’s previous close.

Separately, Zacks Investment Research upgraded Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 price objective for the company in a research report on Monday. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $17.75.

Shares of EQ stock opened at $5.50 on Friday. The company has a 50 day moving average of $6.00. Equillium has a 52 week low of $5.12 and a 52 week high of $19.69.

Equillium (NYSE:EQ) last issued its earnings results on Monday, May 13th. The company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.04).

Several hedge funds and other institutional investors have recently bought and sold shares of EQ. Partner Fund Management L.P. bought a new position in shares of Equillium in the fourth quarter valued at $11,049,000. FMR LLC bought a new position in shares of Equillium in the fourth quarter valued at $6,994,000. BlackRock Inc. acquired a new stake in Equillium during the 4th quarter valued at $1,756,000. Victory Capital Management Inc. raised its stake in Equillium by 7.4% during the 1st quarter. Victory Capital Management Inc. now owns 1,323,381 shares of the company’s stock valued at $10,587,000 after purchasing an additional 90,792 shares during the period. Finally, Northern Trust Corp acquired a new stake in Equillium during the 4th quarter valued at $298,000.

Equillium Company Profile

Equillium, Inc, a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.

Read More: Systematic Risk and Investors

Analyst Recommendations for Equillium (NYSE:EQ)

Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply